Abstract

Chronic migraine is a prevalent and disabling neurological disorder. Preventive treatments are designed to reduce the fre- quency, severity, or duration of migraine attacks. Preventive agents include beta-adrenergic blockers, antidepressants, calcium channel antagonists, serotonin antagonists and anticonvulsants. Although daily oral prophylactic treatments have proven effective, issues such as lack of compliance with daily dosing regimens and adverse effects have limited their usefulness and resulted in a search for other modalities and agents, including botulinum neurotoxin. At 2010, the phase III research evaluating migraine prophylaxis therapy(PREEMPT) paradigm for injecting onabotulinumtoxin A has been shown to be safe, well tolerated, and effective in well designed, controlled clinical trials and was approved by USA, England and Korean FDA.